Background: Elucidating the ontogeny of broadly neutralizing antibodies (NAb) within infected individuals may identify important factors to consider in vaccine development. Although NAbs were not a correlate of risk in the RV144 HIV vaccine trial, B cell priming by vaccination may have accelerated the production of specific NAb lineages after infection. We asked if RV144 vaccine recipients who became infected elicited NAbs that varied in breadth, potency, and specificity compared to RV144 infected placebo recipients.
Methods: Samples from 94 infected RV144 individuals were evaluated for NAbs at 1-3 years post-diagnosis prior to the initiation of ART. Using a high-throughput robotic microneutralization assay, samples were analyzed against a panel of 35 viruses from subtypes A, B, C, D, CRF_01 AE, and CRF_02 AG. Included within this panel were 21 pseudoviruses where the pattern of neutralization can predict NAb specificity. Neutralization breadth, potency, and specificity of the responses observed after infection were compared between the vaccine and placebo recipients.
Results: Aggregate analysis revealed breadth and potency of neutralization were highly correlated (Ï= 0.94; p<0.001; Fig.1). Seventeen (29%) placebos while only 3 (10%) vaccine recipients neutralized >50% of the 35 virus panel (Fig.1). At three years post-diagnosis (956-1198 days), 8 placebo and 1 vaccine recipients neutralized >70% of the panel (Fisher’s exact test, p=0.08), noting that the single vaccine recipient had only received 1 out of the 6 RV144 immunizations (Fig. 1). A trend toward increased breadth in the placebo group compared to the vaccine group (median= 40 vs 30, p=0.08) was also observed. The CD4 binding site and/or MPER were predicted as the dominant NAb specificities from both the placebo and vaccine groups, at 77% and 63% respectively.
Conclusions: We report differences in neutralization breadth and potency between infected vaccine and placebo recipients of RV144. These data suggest a restriction in the vaccine group in the ability to produce broad NAb responses post-infection compared to the placebo group, raising the hypothesis that infected vaccinees define a group with intrinsically less effective HIV-1 immune responses. Further studies will provide a better understanding of the development of antibody responses in HIV-1 infected subjects, the potential role of vaccination on post-infection humoral responses, and the interrelationship between HIV-1 evolution and antibody responses.